History

iQur was founded in April 2003 as a spin-out from the University of Southampton Liver group. Focused on liver disease the company was initially established with three Divisions; Therapeutics, Diagnostics and Drug Distribution. The business model was that the other two Divisions would provide some early support for Therapeutics, the main research and development Division of the company.

As the therapeutics programme has progressed attention has been concentrated on this division. In 2007 iQur sold the Drug Distribution division to Three Rivers Pharmaceuticals. In December 2008 the Diagnostics Division was sold to Delphic Diagnostics, with iQur retaining an exclusive agreement with Siemens to market the Enhanced liver Fibrosis Test. This is a diagnostic for liver damage developed by the Founder.

This has allowed iQur to bring all the company’s resources to bear on the development of its lead therapeutic candidate the Tandem Core Technology (TCT ) vaccine platform.

Current Configuration

Prof William Rosenberg is the Founder and CEO of the company.

The Board is chaired by Mr Jack Boyer and comprised of non-executive members Dr Bruce Campbell and Mrs Brenda Reynolds. Mr Vic Laville is the Director of Finance.  Dr Mike Whelan is Head of Scientific Operations is an experienced vaccine biologist and immunologist. 

iQur maintains a molecular biology team at the University of Leeds from where the Tandem Core Technology was licensed and an immunology team at University College London where Prof Rosenberg and Dr Whelan are based.